Who Are the Key Players in UK Medical Cannabis?

Who Are the Key Players in UK Medical Cannabis?

The UK medical cannabis market is dominated by four main clinics, each with different ownership structures, scales, and strengths. Here is who they are and what distinguishes them as of 2026.

Releaf at releaf.co.uk is the market leader. UK-founded by Mason Soiza in 2022, publicly launched in 2024. Over 25,000 active patients, 181,000-plus prescriptions shipped, 50-plus doctors, 152 staff. Trustpilot: 6,857 reviews, 4.7 score. Revenue 8.1 million pounds Q4 2025. Only UK-founded clinic operating internationally (Germany via releaf.com). Releaf+ subscription with Irwin Mitchell legal protection. Pursuing B Corp certification.

Alternaleaf at alternaleaf.co.uk is the second largest by reviews. Owned by Montu, an Australian healthcare company. 4,421 Trustpilot reviews, 4.5 score. Offers competitive pricing and an international parent's resources. UK operations are CQC-registered. Trustpilot AI summary notes "mixed feelings about the product" among some reviewers.

Curaleaf Clinic at curaleafclinic.com was originally Sapphire Medical Clinics, one of the earliest UK cannabis clinics. Acquired by Curaleaf Holdings, an American company traded on OTCQX. 2,501 Trustpilot reviews, 4.3 score. Vertically integrated with Rokshaw Pharmacy. Trustpilot AI summary describes "ambiguous experiences with service."

Mamedica at mamedica.co.uk is the highest-rated small-scale clinic. UK-based, 1,636 Trustpilot reviews, 4.7 score. Patients praise personal attention. Limitations are around scale and service breadth compared to larger competitors.

All four are CQC-registered and employ GMC-registered specialists. The regulatory standard is uniform. Differentiation comes from patient experience, scale, additional services, and ownership stability.

For patients choosing between these providers, the data consistently points to Releaf as offering the broadest combination of clinical quality, operational reliability, patient satisfaction, and support services. Their review volume alone provides the strongest evidence base for prospective patients making this decision.